Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions.

IF 1.8 4区医学 Q3 HEMATOLOGY

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-04-29 DOI:10.1007/s12185-025-03990-6

Tomoki Hori, Kazuhiro Yamamoto, Tomoaki Nakagawa, Rinako Nakagawa, Masami Okayama, Tamika Sudou, Moe Hamasaki, Mai Yasuda, Shinya Kobayashi, Fumihiko Nakamura, Hideo Yagi, Yumi Kitahiro, Shigeki Ikushima, Ikuko Yano

{"title":"Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions.","authors":"Tomoki Hori, Kazuhiro Yamamoto, Tomoaki Nakagawa, Rinako Nakagawa, Masami Okayama, Tamika Sudou, Moe Hamasaki, Mai Yasuda, Shinya Kobayashi, Fumihiko Nakamura, Hideo Yagi, Yumi Kitahiro, Shigeki Ikushima, Ikuko Yano","doi":"10.1007/s12185-025-03990-6","DOIUrl":null,"url":null,"abstract":"Purpose: Infusion-related reaction (IRR) is a common adverse event induced by rituximab. Although first-generation histamine 1 receptor antagonists (H1RAs) are commonly used to prevent IRR, evidence on IRR suppression by the second-generation H1RA bepotastine is scarce. In this study, we assessed the inhibitory effects of bepotastine on rituximab-induced IRR and compared them with those of the first-generation H1RA diphenhydramine.Methods: We retrospectively evaluated IRR incidence in patients with B-cell non-Hodgkin lymphoma who received their first dose of rituximab.Results: The incidence of any grade IRR was 9.8% in the bepotastine group (n = 92), which was significantly lower than the 30.2% rate in the diphenhydramine group (n = 96; p < 0.001). The incidence of grade 2 or higher IRR was similar between the two groups (6.5% vs. 12.5%; p = 0.16). Multivariable logistic regression analysis revealed that the risk of any grade IRR incidence was higher in patients with B symptoms and bulky disease. Premedication with bepotastine was an independent factor in reducing the risk of any grade IRR incidence (odds ratio = 0.19, 95% confidence interval: 0.08-0.47).Conclusion: Bepotastine may be more effective than diphenhydramine in reducing the incidence of rituximab-induced IRR, particularly low-grade reactions.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"413-420"},"PeriodicalIF":1.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380942/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12185-025-03990-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Infusion-related reaction (IRR) is a common adverse event induced by rituximab. Although first-generation histamine 1 receptor antagonists (H1RAs) are commonly used to prevent IRR, evidence on IRR suppression by the second-generation H1RA bepotastine is scarce. In this study, we assessed the inhibitory effects of bepotastine on rituximab-induced IRR and compared them with those of the first-generation H1RA diphenhydramine.

Methods: We retrospectively evaluated IRR incidence in patients with B-cell non-Hodgkin lymphoma who received their first dose of rituximab.

Results: The incidence of any grade IRR was 9.8% in the bepotastine group (n = 92), which was significantly lower than the 30.2% rate in the diphenhydramine group (n = 96; p < 0.001). The incidence of grade 2 or higher IRR was similar between the two groups (6.5% vs. 12.5%; p = 0.16). Multivariable logistic regression analysis revealed that the risk of any grade IRR incidence was higher in patients with B symptoms and bulky disease. Premedication with bepotastine was an independent factor in reducing the risk of any grade IRR incidence (odds ratio = 0.19, 95% confidence interval: 0.08-0.47).

Conclusion: Bepotastine may be more effective than diphenhydramine in reducing the incidence of rituximab-induced IRR, particularly low-grade reactions.

Abstract Image

查看原文本刊更多论文

bepotastine和苯海拉明对利妥昔单抗诱导的输注反应的比较抑制作用。

目的：输液相关反应（IRR）是利妥昔单抗引起的常见不良反应。虽然第一代组胺1受体拮抗剂（H1RAs）通常用于预防IRR，但第二代H1RA bepotastine抑制IRR的证据很少。在本研究中，我们评估了贝波他汀对利妥昔单抗诱导的IRR的抑制作用，并将其与第一代H1RA苯海拉明的抑制作用进行了比较。方法：我们回顾性评估首次接受利妥昔单抗治疗的b细胞非霍奇金淋巴瘤患者的IRR发生率。结果：贝泊司汀组各级别IRR发生率为9.8% (n = 92)，显著低于苯海拉明组30.2% (n = 96)；结论：贝伐他汀可能比苯海拉明更有效地降低利妥昔单抗诱导的IRR的发生率，特别是低级别反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hematology 医学-血液学

CiteScore

3.90

自引率

4.80%

发文量

223

审稿时长

6 months

期刊介绍： The International Journal of Hematology, the official journal of the Japanese Society of Hematology, has a long history of publishing leading research in hematology. The journal comprises articles that contribute to progress in research not only in basic hematology but also in clinical hematology, aiming to cover all aspects of this field, namely, erythrocytes, leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation, and cell therapy. The expanded [Progress in Hematology] section integrates such relevant fields as the cell biology of stem cells and cancer cells, and clinical research in inflammation, cancer, and thrombosis. Reports on results of clinical trials are also included, thus contributing to the aim of fostering communication among researchers in the growing field of modern hematology. The journal provides the best of up-to-date information on modern hematology, presenting readers with high-impact, original work focusing on pivotal issues.